In summary, the study provides evidence for the rapid production of vaccine-specific antibodies, both IgA and IgG. Moreover, neutralization capacity for breastmilk was observed in all samples. This study also indicates the potential protection conferred on breastfed infants by the administration of t...
, Oxford COVID Vaccine Trial Group T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial Nat. Med., 27 (2021), pp. 270-278 CrossrefView in ScopusGoogle Scholar Flores-Alanis et al., 2021 A. Flores-Alanis, A. ...
First insights into the immunogenicity of the BNT162b2 vaccine in an immunocompromised patient population have been reported as interim results from the SOAP-trial on can- cer patients: the immune response following the prime dose was low in solid cancer patients (< 40%) and very low in ...
Figure 1. Trial profile for prospective (A) and retrospective (B) cohort All participants in the prospective study were advised, both orally and in writing, about the study and provided written informed consent to participate. The entire study (prospective and retrospective parts) was approved by...
Meta-analysis results of the comparative effectiveness of mRNA-1273 and BNT162b2 in the base-case are shown in Figs.2,3,4,5and in the subgroups of groups of medical conditions and individual comorbidities in FigsS1–S10. Fig. 2 Summary of meta-analysis results on clinical effectiveness outco...
Immunogenicity and Reactogenicity of BNT162b2 Booster in ChAdOx1-S-Primed Participants (CombiVacS): A Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial. Lancet 2021, 398, 121–130. [Google Scholar] [CrossRef] van Gils, M.J.; Lavell, A.; van der Straten, K.; Appelman, ...
We observed a statistically significant decrease in the number of new cancer diagnoses and in new clinical trial enrollment, as well as a change in drug administration, with less intravenous and more oral drug administration [17]. Before any explanation can be found, it is essential to define ...
et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: An interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.Lancet HIV2021,8, e568–e580. [Google Scholar] [...